Amgen Yönetim
Yönetim kriter kontrolleri 3/4
Amgen's CEO is Bob Bradway, appointed in May 2010, has a tenure of 14.5 years. total yearly compensation is $22.64M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $200.71M. The average tenure of the management team and the board of directors is 4.8 years and 7.9 years respectively.
Anahtar bilgiler
Bob Bradway
İcra Kurulu Başkanı
US$22.6m
Toplam tazminat
| CEO maaş yüzdesi | 7.9% |
| CEO görev süresi | 14.5yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 7.9yrs |
Son yönetim güncellemeleri
Recent updates
Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02
Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
Tazminat ve Piyasa: Bob's total compensation ($USD22.64M) is above average for companies of similar size in the US market ($USD12.87M).
Tazminat ve Kazançlar: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Bradway (61 yo)
14.5yrs
Görev süresi
US$22,643,650
Tazminat
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 14.5yrs | US$22.64m | 0.12% $ 200.7m | |
| Executive VP & CFO | 4.8yrs | US$7.57m | 0.0046% $ 7.9m | |
| Executive Vice President of Operations | 8.3yrs | US$7.21m | 0.011% $ 19.6m | |
| Executive VP & CTO | less than a year | US$7.90m | 0.0094% $ 16.1m | |
| Executive Vice President of Global Commercial Operations | 6.2yrs | US$8.24m | 0.0075% $ 12.8m | |
| Chief Accounting Officer & VP of Finance | 1.3yrs | Veri yok | 0.00056% $ 960.9k | |
| Executive VP of Research & Development and Chief Scientific Officer | less than a year | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Executive VP | 9.3yrs | US$7.24m | 0.0046% $ 8.0m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.8yrs | Veri yok | 0.0013% $ 2.2m | |
| Senior Vice President of Global Marketing & Access | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Human Resources | 2.8yrs | Veri yok | 0.0012% $ 2.0m |
4.8yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: AMGN's management team is considered experienced (4.8 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$22.64m | 0.12% $ 200.7m | |
| Lead Independent Director | 11.9yrs | US$419.92k | 0.0013% $ 2.2m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | Veri yok | |
| Co-Chair of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.3yrs | US$359.92k | 0.000080% $ 137.3k | |
| Independent Director | 7.8yrs | US$369.92k | 0.00023% $ 394.7k | |
| Independent Director | 11.1yrs | US$379.92k | 0.0023% $ 3.9m | |
| Independent Director | 8.1yrs | US$360.29k | 0.000080% $ 137.3k | |
| Independent Director | 6.5yrs | US$359.92k | 0.00015% $ 257.4k | |
| Independent Director | 12.5yrs | US$339.92k | 0.00051% $ 875.1k | |
| Independent Director | 6.9yrs | US$359.92k | 0.0012% $ 2.1m | |
| Independent Director | 3.3yrs | US$366.47k | 0.00017% $ 291.7k |
7.9yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AMGN's board of directors are considered experienced (7.9 years average tenure).